# A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00363896** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 843 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Aclidinium bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00363896
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 843 (ACTUAL)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363896, "A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00363896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*